Redeye provides a short comment on today's order announcement from Scandinavian ChemoTech, this is the second, rather significant, order within the past c30 days. With recent sales momentum and regulatory cost savings from reduced activity in Human Care, it seems the company could be on track for profitability on a run-rate basis already in 2025. Our fair value range is maintained but derisked.
LÄS MER
